We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery.
- Authors
Sénac, J S; Chandler, R J; Sysol, J R; Li, L; Venditti, C P
- Abstract
Methylmalonic acidemia (MMA), an inherited metabolic disorder caused by deficient activity of methylmalonyl-CoA mutase, carries a poor prognosis for long-term survival. While administration of a recombinant adeno-associated virus serotype 8 vector (rAAV8) can rescue Mut−/− mice from neonatal lethality and provide sustained phenotypic correction, translation of gene therapy to human subjects will likely require multiple rounds of systemic administration and, ideally, the use of a vector that transduces the kidney. To examine the effectiveness of alternative rAAVs in the treatment of MMA, a serotype 9 rAAV expressing the Mut cDNA was constructed and delivered to newborn Mut−/− mice (n=11). rAAV9 gene therapy directed hepatic transgene expression within 24 h and effectively rescued the Mut−/− mice from lethality, conferred long-term survival, markedly improved metabolism and resulted in striking preservation of renal function and histology. Systemic readministration of the vector at a dose similar to that used in human clinical trials (2.5 × 109 GC of rAAV9 per gram) to older, treated Mut−/− mice (n=5) lowered circulating metabolites, increased in vivo propionate oxidative capacity and produced transgene expression in the kidney and liver. Our data support the use of an rAAV9 vector in the acute and chronic treatment of MMA, and highlight the renal tropism afforded by this novel serotype.
- Subjects
GENE therapy; METHYLMALONIC acid; ACIDOSIS; ADENOVIRUSES; PHENOTYPES; MOLECULAR genetics; LABORATORY mice
- Publication
Gene Therapy, 2012, Vol 19, Issue 4, p385
- ISSN
0969-7128
- Publication type
Article
- DOI
10.1038/gt.2011.108